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Abstract
Background: The extent to which baseline couple characteristics affect the probability of live birth and adverse perinatal
outcomes after assisted conception is unknown.
Methods and Findings: We utilised the Human Fertilisation and Embryology Authority database to examine the predictors
of live birth in all in vitro fertilisation (IVF) cycles undertaken in the UK between 2003 and 2007 (n= 144,018). We examined
the potential clinical utility of a validated model that pre-dated the introduction of intracytoplasmic sperm injection (ICSI) as
compared to a novel model. For those treatment cycles that resulted in a live singleton birth (n= 24,226), we determined
the associates of potential risk factors with preterm birth, low birth weight, and macrosomia. The overall rate of at least one
live birth was 23.4 per 100 cycles (95% confidence interval [CI] 23.2–23.7). In multivariable models the odds of at least one
live birth decreased with increasing maternal age, increasing duration of infertility, a greater number of previously
unsuccessful IVF treatments, use of own oocytes, necessity for a second or third treatment cycle, or if it was not unexplained
infertility. The association of own versus donor oocyte with reduced odds of live birth strengthened with increasing age of
the mother. A previous IVF live birth increased the odds of future success (OR 1.58, 95% CI 1.46–1.71) more than that of a
previous spontaneous live birth (OR 1.19, 95% CI 0.99–1.24); p-value for difference in estimate ,0.001. Use of ICSI increased
the odds of live birth, and male causes of infertility were associated with reduced odds of live birth only in couples who had
not received ICSI. Prediction of live birth was feasible with moderate discrimination and excellent calibration; calibration was
markedly improved in the novel compared to the established model. Preterm birth and low birth weight were increased if
oocyte donation was required and ICSI was not used. Risk of macrosomia increased with advancing maternal age and a
history of previous live births. Infertility due to cervical problems was associated with increased odds of all three
outcomes—preterm birth, low birth weight, and macrosomia.
Conclusions: Pending external validation, our results show that couple- and treatment-specific factors can be used to
provide infertile couples with an accurate assessment of whether they have low or high risk of a successful outcome
following IVF.
Please see later in the article for the Editors’ Summary.
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Introduction
In-vitro fertilisation (IVF) is now widely used for the treatment
of infertility, and validated age-stratified national success rates and
outcomes are published annually [1,2,3]. To facilitate patient
counselling, clinical decision-making, and access to health care
provision, prediction models for live birth after IVF have been
constructed [4]. However, these studies have been limited by their
sample size, development before the introduction of intracytoplas-
mic sperm injection (ICSI), or lack of validation in external
populations [5,6,7,8,9]. Established multivariable prediction
models may therefore not be applicable to contemporary couples
seeking treatment. Consequently, clinicians and regulatory bodies
have not adopted prediction models and predominantly quote age-
related success rates [1,2,3].
Given the known complications with multiple gestations and
prematurity, the focus has moved to defining the most appropriate
IVF outcome variable as a singleton term live birth [10,11,12]. Low
birth weight and macrosomia are also known to be associated with
immediate and long-term risk to offspring heath [13], and IVF
singletons are at increased risk of these complications [14,15]. It is
now recognised that factors leading to infertility may be responsible
for adverse perinatal outcome rather than the process itself
[16,17,18,19]; however, which parental characteristics of infertile
couples contribute to adverse perinatal outcomes in IVF singletons
and can thereby be targeted for intervention remain unknown.
In this prospective cohort study of 144,018 treatment cycles we
assessed the extent to which baseline characteristics can be used to
predict live birth after IVF-assisted conception, and for those
cycles in which a singleton pregnancy was achieved we identified
which factors were associated with preterm delivery, low birth
weight, and macrosomia.
Methods
Source of Data
The UK Human Fertilisation and Embryology Authority
(HFEA), which is responsible for the regulation of assisted
conception treatment in the UK, has had a Parliamentary
statutory obligation to prospectively collect baseline information
and birth outcomes on all licensed fertility treatment cycles
performed in the UK since 1991 [7]. All treatment cycles and
outcomes registered on the HFEA database between January 2003
and December 2007 were used in our study, with the final analysis
cohort details and exclusion criteria provided in Figure 1 [20].
Treatment cycles that were for storage or donation of gametes,
were not IVF, or were frozen embryo transfers were excluded.
Although there is a move to greater use of frozen embryo cycles we
excluded these from our analyses to be consistent with previous
publications, including that by Templeton et al. [7] in which the
established model was developed. Furthermore, during the time
studied very few elective single embryo transfers were performed
(,0.05% of all cycles). HFEA data relating to treatments between
April 1999 and March 2002 were not verified by licensed
treatment centres and are therefore deemed less accurate.
Furthermore, few treatment cycles had treatment with ICSI
before and during this period. Whilst data have been collected
beyond 2007, validation checks on the computerised data
undertaken by HFEA are currently complete only to December
2007. Anonymised data were provided by the HFEA per cycle of
treatment rather than for individual women, so our outcomes are
expressed as rates and/or odds per cycle of treatment (rather than
per individual woman). Ethical approval of the study was provided
by the HFEA.
Measurements
Maternal age, duration and cause of infertility, previous number
of IVF attempts, number of previous spontaneous and IVF live
births, source of gametes, and cycle number were recorded at the
time of treatment. Duration of fertility, number of previous IVF
attempts, number of previous pregnancies, number of previous
IVF pregnancies, and total number of previous live births were all
categorised in accordance with the previous analysis by Templeton
[7]. Cycle number was collapsed, with more than three cycles as
one category, because of small numbers. Live birth was defined as
a baby born alive after 24 wk gestation. Our main outcome was at
least one live birth, which was defined as any birth event in which
at least one baby was born alive and survived for more than 1 mo.
This outcome is consistent with previous publications, including
that by Templeton et al. [7] used to define the established
prediction model. In a sensitivity analysis we repeated associations
with this main outcome after exclusion of multiple pregnancies,
defined as those in which two or more fetal heartbeats were noted
at 8 wk gestation.
For assessment of perinatal outcomes in cycles with a singleton
live birth, gestational age at birth was defined as completed weeks
of gestation. For the main outcome of preterm we examined
multivariable associations with preterm birth, defined as #36
completed weeks; we also examined associations with extreme
preterm (,33 wk). Birth-weight outcomes were supplied in 500 g
increments and categorised as low birth weight (LBW ,2.5 kg),
normal ($2.5 to ,4.0 kg) or macrosomic ($4 kg). In these
analyses we included only cycles in which there was one heartbeat
at 8 wk gestation and one live birth (i.e. these were singleton live
births).
Statistical Methods
We performed univariable and multivariable logistic regression
to assess associations with at least one live birth. Given that the
historical multivariable Templeton model [7] had been externally
validated we first tested its predictive ability. We used the reported
characteristics that were associated with live birth and their
respective regression coefficients from that model to generate the
probability of live birth in our cohort (see Text S1 for full details of
these calculations) [7]. The predictive ability of the model was
assessed by determining the discrimination, using the area under
the curve of receiver operator characteristics (AUROC), and its
Figure 1. Definition of eligible cohort and analysis sample. IVF,
In-vitro fertilisation, GIFT, gamete intra-fallopian tube transfer, ZIFT,
zygote intra-fallopian tube transfer.
doi:10.1371/journal.pmed.1000386.g001
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calibration. Calibration was assessed by ranking participants into
tenths based on their predicted risk for the Templeton prediction
model, and then within each tenth comparing the predicted mean
rate to the observed rate of live birth.
The multivariable logistic regression model formed the basis of
our novel prediction model of live birth. In the novel prediction
model we used the same characteristics as those used in the
Templeton model but included all causes of infertility (Templeton
includes only tubal versus all other causes), and allowed the
coefficients for this and all other variables to be newly derived, and
included four additional characteristics—the source of the egg
(donor or patient’s own), type of hormonal preparation used
(antioestrogen, gonadotrophin, or hormone replacement therapy),
whether or not ICSI was used, and the number of the treatment
cycle (1, 2 or$3). We tested all two-way interactions between pairs
of predictors included in our multivariable analyses and used a
Bonferroni-corrected (for multiple testing) p-value threshold of 0.05
to define statistical evidence of an interaction. The discrimination
and calibration of this novel model was assessed as described above.
The AUROC between the Templeton model and our model was
compared using the ROCCOMP command in Stata [21].When we
repeated the multivariable analyses using 1,000 bootstrap replica-
tions, the estimates and their standard errors were essentially the
same and results are presented here without bootstrapping.
Lastly, we examined model reclassification by determining the
integrated discrimination improvement (IDI) of the novel
prediction model compared to the original Templeton model
[7]. The IDI is a summary measure of the extent to which a new
prediction model increases risk prediction in individuals who
ultimately have the outcome of interest [22], and reduces risk
prediction in those who remain healthy in comparison to the
established risk prediction model (in this case the Templeton
model [7]).
To explore risk factors for adverse perinatal outcomes (preterm,
extreme preterm, low birth weight, and macrosomia) we used
logistic regression to examine the univariable and independent
multivariable associations of all risk factors assessed in the
multivariable analyses of at least one live birth, as described
above. The selection of these potential risk factors for adverse
perinatal outcomes was based on previous studies and the
plausibility that risk factors that influence odds of live birth are
also likely to affect gestational age and birth weight. For
associations with preterm as the outcome we additionally adjusted
for mean birth weight, and for outcomes with low birth weight and
macrosomia we adjusted for mean gestational age. These analyses
were conducted only for cycles in which there was only one
heartbeat at 8 wk gestation and at least one live birth.
All statistical analyses were performed using Stata version 11
(StataCorp LP).
Dealing with Missing Data
For the vast majority of variables there was no missing data;
3.9% of cycles had missing data on method of hormonal
preparation used and 8.4% had missing data on duration of
infertility; overall 12% of the eligible cohort had some missing data
(Figure 1 and Table S1). Univariable associations were very similar
when maximum numbers for each variable were used (Table S2)
and when only those with complete data were used (Table 1),
suggesting that missing data did not result in bias.
Results
Figure 1 shows how we established the eligible cohort of IVF
treatment cycles (N=163,425) and the sample used for the main
multivariable analyses (i.e. without any missing data N=144,018;
88% of eligible). Table S1 shows the study characteristics.
Amongst the 163,425 eligible cohort, the overall rate of at least
one live birth was 23.4 per 100 cycles (95% CI 23.2–23.7). Rates
of successful live birth increased linearly over time from 22.7 per
100 cycles in 2003 to 24.9 per 100 cycles in 2007 (p,0.001 for
linear trend) (Figure S1).
Table 1 shows univariable and multivariable associations of live
birth. The odds of successful live birth decreased with increasing
maternal age, increasing duration of infertility, greater number of
previously unsuccessful IVF treatments, when the woman’s own
egg (as opposed to donor) was used, and when this was the second
or third (as opposed to first) treatment cycle. Odds of successful live
birth were lower when the cause of infertility was tubal,
anovulatory, or cervical disease or when it was due to a male
cause. Women who had at least one previous live birth (either
natural or with IVF) had increased odds of a successful live birth
with this cycle, as did those in whom gonadotrophin or hormone
replacement (as opposed to antioestrogens) were used and ICSI
was used with IVF. A previous IVF live birth increased the odds of
future success (OR 1.58, 95% CI 1.46–1.71) more than previous
spontaneous live birth (OR 1.19, 95% CI 0.99–1.24); p-value for
difference in estimate ,0.001 (estimated using 1,000 bootstrap
replications to estimate standard errors of differences between the
log odds between the two regression coefficients).
There was statistical evidence for four interactions, and
stratified analyses reflecting these interactions are shown in Table
S3 (for interactions with age) and Table S4 (for interactions with
ICSI). The increased odds of success in cycles in which the
duration of infertility was less than one year increased with
increasing maternal age, though only a very small proportion of all
cycles were in the category of less than one year duration of
infertility. The reduced odds of successful outcome amongst own
versus donor oocytes strengthened with increasing age. In couples
who had not used ICSI all three causes—male infertility, infertility
due to cervical disorders, and infertility due to a combination of
causes—were associated with reduced odds of live birth, whereas
there were no such associations in those using ICSI. Requiring
three or more treatment cycles was associated with reduced odds
of live birth in those in which ICSI was used, but not where it was
not used. These four interactions were included in our novel
prediction model, which is described in Text S2.
Table 2 shows the AUROC for each of the Templeton and our
new prediction models, with statistically significant improvement
in discrimination for our novel model. Figure 2 and Table 3 show
the observed to predicted rate of successful live birth by tenths of
the distribution of the linear prediction models for each of the
models. Calibration was poor with the Templeton model, which
markedly underestimated the likelihood of successful live birth
across the entire distribution of risk, particularly in those at lowest
risk. By contrast the novel model had excellent calibration and
reclassified cycle probability of a live birth in a way that improved
upon the original Templeton model (IDI= 2.1%, p,0.001
comparing the novel model to the Templeton [7]).
Of the 144,018 cycles 9931 (7%) were multiple pregnancies (i.e.
had two or more fetal heart beats noted at 8 wk gestation). Of
these, 1,264 (13%) resulted in one live birth, 7,925 (80%) in two
live births, and 109 (1%) in three live births; 633 (6%) did not
result in a live birth. When we removed these 9,931 cycles from
our analyses results were essentially unchanged from those
presented here. For example, Table S5 shows the univariable
and multivariable associations of potential predictors with live
birth after these exclusions (i.e., the equivalent of Table 1 in this
paper). The AUROC, observed to predicted ratios and IDI were
Predicting IVF Outcome
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Table 1. Associations of potential predictors for live birth following IVF.
Characteristic Categories
Univariable Odds Ratio
of Live Birth (95% CI)
Multivariablea Odds Ratio
of Live Birth (95% CI) p-Valueb
Maternal age (years) 18–34 1 1 ,0.001
35–37 0.77 (0.75–0.79) 0.78 (0.76–0.81)
38–39 0.53 (0.51–0.55) 0.53 (0.51–0.56)
40–42 0.29 (0.28–0.30) 0.29 (0.28–0.31)
43–44 0.10 (0.09–0.12) 0.10 (0.09–0.12)
45–50 0.15 (0.12–0.19) 0.12 (0.09–0.15)
Duration of infertility (years) ,1 1.48 (1.34–1.65) 1.51 (1.35–1.68) ,0.001
1–3 1.10 (1.07–1.13) 1.11 (1.08–1.15)
4–6 1 1
7–9 0.91 (0.87–0.94) 0.94 (0.91–0.98)
9–12 0.81 (0.76–0.85) 0.87 (0.82–0.92)
.12 0.71 (0.67–0.75) 0.89 (0.84–0.95)
Cause of infertility Unknown 1 1 ,0.001
Tubal only 0.94 (0.90–0.97) 0.87 (0.83–0.90)
Anovulatory only 0.93 (0.88–0.98) 0.95 (0.90–1.00)
Endometriosis only 1.05 (0.98–1.13) 0.96 (0.89–1.03)
Cervical only 0.41 (0.20–0.85) 0.39 (0.19–0.82)
Male only 1.16 (1.13–1.20) 0.91 (0.87–0.95)
Combination known causes 1.01 (0.96–1.06) 0.88 (0.83–0.92)
Number of previous unsuccessful IVF 0 1 1 ,0.001
1 0.74 (0.70–0.79) 0.72 (0.65–0.81)
2 0.69 (0.64–0.76) 0.70 (0.62–0.80)
3 0.74 (0.66–0.84) 0.77 (0.66–0.91)
4 0.51 (0.42–0.62) 0.55 (0.45–0.69)
$5 0.57 (0.48–0.69) 0.68 (0.55–0.83)
Mutually exclusive categories
of previous IVF and obstetric history
No previous IVF, 0 pregnancy 1 1 ,0.001
No previous IVF, at least 1
pregnancy, 0 live births
0.88 (0.86–0.91) 1.03 (0.99–1.06)
No previous IVF, at least 1
pregnancy, at least 1 live birth
0.92 (0.88–0.96) 1.19 (1.14–1.24)
Previous IVF, 0 pregnancy 0.72 (0.68–0.76) 1.14 (1.01–1.28)
Previous IVF, at least 1
pregnancy, 0 live birth
0.68 (0.64–0.73) 1.02 (0.93–1.11)
Previous IVF, at least 1
pregnancy, at least 1 live birth
1.10 (1.03–1.17) 1.58 (1.46–1.71)
Hormonal preparation Antioestrogen 1 1 ,0.001
Gonadatrophin 1.43 (1.24–1.63) 1.33 (1.15–1.53)
Hormone replacement 1.61 (1.38–1.89) 1.55 (1.31–1.82)
Cycle number 1 1 1 ,0.001
2 0.80 (0.78–0.83) 0.85 (0.82–0.87)
$3 0.76 (0.74–0.79) 0.88 (0.85–0.91)
Source of egg Donor 1 1 ,0.001
Patient 0.87 (0.74–1.02) 0.38 (0.32–0.45)
Treatment type IVF 1 1 ,0.001
ICSI plus IVF 1.28 (1.25–1.31) 1.27 (1.23–1.31)
N=144,018 analysis cohort with complete data on all variables included in any model.
aMultivariable adjusted = mutual adjustment for all variables listed in column one.
bp-Value for multivariable association; all p-values are likelihood ratio tests of null hypothesis that the odds are the same for each category (i.e., they do not assume
linearity).
doi:10.1371/journal.pmed.1000386.t001
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the same as those presented in Tables 2 and 3 with these
exclusions.
Table 4 provides examples of how our novel prediction model
could be used in clinical practice to give an estimate of a couple’s
probability of achieving a live birth in a given cycle of treatment.
This illustrates not only the clinical use of this model (which we
have developed into a freely available computer programme,
http://www.IVFpredict.com, and iPhone/Android application,
IVFpredict) but also how both couple characteristics and
treatment choice influence prognosis.
Of the 144,018 cycles included in our main analyses for
prediction of successful live birth, there were 24,226 live singleton
births; 24,096 (99.5%) of these had gestational age data and
24,050 (99.3%) had birth weight data. Mean (SD) gestational age
was 38.98 (2.12) completed weeks, with 472 (2.0%) being less than
33 wk, 1,598 (6.6%) between 33–36 weeks and 22,026 (91.4%) 37
or greater weeks. Mean (SD) birth weight was 3.277 (0.629) kg,
with 2,100 (8.7%) low birth weight (,2.5 kg), 19,704 (81.9%) a
healthy birth weight, and 2,246 (9.3%) macrosomic ($4.0 kg).
Table S6 shows the univariable associations of risk factors preterm
(,37 completed weeks), low birth weight (,2.5 kg) and macro-
somia ($4.0 kg). Table 5 shows the multivariable associations of
these risk factors with preterm birth, low birth weight, and
macrosomia. In multivariable analyses the odds of both preterm
birth and low birth weight in singleton IVF live births were
reduced when the woman’s (rather than donor) egg was used and
when ICSI was used. The odds of low birth weight were also
reduced with increasing maternal age and with a history of
previous pregnancy (either spontaneous or following IVF). Odds of
macrosomia increased with increasing maternal age and in cycles
in which there was history of a previous pregnancy (either
spontaneous or IVF). Odds of all three factors—preterm birth, low
birth weight, and macrosomia—were increased when infertility
was due to a cervical disorder. Tubal causes of infertility were
associated with increased odds of preterm birth, anovulatory
causes with low birth weight, and male causes of infertility with
macrosomia. Table S7 shows univariable and multivariable
associations with extreme preterm birth (,33 wk; n=472).
Characteristics that were associated with preterm birth in general
were also associated with extreme preterm birth. In addition,
extreme preterm birth was lower in 38- to 39-year-olds compared
to all other ages and was increased in those who had a previous
history of IVF.
Discussion
In this study we identify precise estimates of the strength and
independence of the factors affecting the odds of IVF success and
their association with adverse perinatal outcome. To date,
successful prediction of live birth after assisted conception has
been limited, with a recent systematic review [4] finding that
models were limited by their sample size, incorporating fewer
than 3,100 cycles or couples and their lack of external validation.
The notable exception was the model of Templeton et al., which
analysed 36,961 treatment cycles undertaken in the UK between
1991 and 1994 and was validated in a population of 1,253
couples receiving IVF treatment in The Netherlands between
1991 and 1999 [7,23]. Since then, ICSI for male factor infertility
has been widely adopted, and consequently we demonstrate that
this previously validated model, although showing reasonable
discrimination, is poorly calibrated and of limited use in
contemporary populations. We have developed a new model,
which encompasses a series of new measures including use of
donor oocytes, ICSI, cycle number, and whether there had been
a previous spontaneous or IVF-related live birth or fetal loss.
Using this novel model we can statistically significantly improve
the overall prediction of live birth as assessed by area under the
curve and attain excellent calibration with accurate identification
of couples with a poor, moderate, or good prognosis. We also find
that maternal characteristics, in particular maternal age, source
of the oocyte and cervical causes of infertility are strongly
associated with the risk of low birth weight and preterm delivery
in singleton live births resulting from IVF. Notably, some of these
associations were in the opposite direction to those seen for
successful live birth. Thus, in women who successfully have a
singleton live birth with IVF, the risk of low birth weight is
reduced in older compared with younger women and both low
birth weight and preterm are reduced when the woman’s own
embryo has been used.
Table 2. AUROC for the Templeton and novel method of predicting live birth with IVF.
Model AUROC (95% Confidence Interval) p-Value Comparing Models
Templeton 0.6184 (0.6152–0.6217) ref
Novel model 0.6335 (0.6202–0.6367) ,0.001
N=144,018 analysis cohort with complete data on all variables included in any model. Templeton: As in reference [7], to date the only externally validated prediction
model. Novel model: using the same variables as Templeton but allowing them to have different multivariable coefficients to those originally derived by Templeton and
including terms for all causes of infertility (rather than just tubal versus other, as in the original Templeton) and four additional predictors: type of hormonal preparation,
whether egg came from patient or donor, number of treatment cycles, and whether ICSI was used with the IVF.
doi:10.1371/journal.pmed.1000386.t002
Figure 2. Ratios of predicted to observed live birth rate using
two prediction models. N=144,018 cycles of IVF treatment in the
United Kingdom. Long dashed line, Templeton model; short dashed
line, novel prediction model 2; red horizontal line, ratio of 1 (i.e., perfect
prediction) for all levels of risk.
doi:10.1371/journal.pmed.1000386.g002
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The use of assisted conception has increased dramatically over
recent years, with concomitant increases in success rates, in part
driven by the widespread uptake of ICSI for male factor infertility
[24]. The importance of ICSI in general and in particular causes
of infertility is demonstrated in our study by its association with
increased odds of successful live birth and by the fact that couples
with male causes of infertility, cervical causes, or combined causes
have reduced odds of success if ICSI has not been used, but are
unrelated to success if ICSI has been used. Recent technical
advances have, however, failed to overcome the reduction in
success rates associated with increasing duration of infertility,
necessity for repeated IVF attempts, or increasing maternal age, all
Table 3. Calibration of the two prediction models.
Tenth of the Dis-
tribution of the
Linear Predictor Templeton Prediction Modela Novel Prediction Modelb
Observed Live Birth
Rate per 100 Cycles of
Treatment (95% CI)
Predicted Live Birth
Rate per 100 Cycles of
Treatment (95% CI)
Ratio
Predicted to
Observed
Observed Live Birth
Rate per 100 Cycles of
Treatment (95%CI)
Predicted Live Birth
Rate per 100 Cycles of
Treatment (95%CI)
Ratio
Predicted
to Observed
Lowest 10th 8.36
(7.91–8.81)
3.57
(3.54–3.59)
0.43 7.66
(7.23–8.09)
7.23
(7.18–7.28)
0.94
2nd 13.66
(13.10–14.22)
6.44
(6.43–6.45)
0.47 13.21
(12.66–13.76)
13.16
(13.13–13.18)
1.00
3rd 18.67
(18.04–19.29)
8.45
(8.43–8.46)
0.45 18.15
(17.53–18.78)
18.00
(17.99–18.02)
1.00
4th 22.77
(22.14–23.40)
10.26
(10.25–10.26)
0.45 20.42
(19.76–21.08)
21.10
(21.09–21.11)
1.03
5th 23.30
(22.51–24.07)
11.61
(11.60–11.62)
0.50 23.40
(22.71–24.08)
23.63
(23.62–23.63)
1.01
6th 25.41
(24.77–26.05)
13.31
(13.30–13.32)
0.52 24.87
(24.18–25.56)
25.57
(25.57–25.59)
1.03
7th 29.93
(29.22–30.64)
13.69
(13.69–13.69)
0.46 27.04
(26.30–27.77)
27.43
(27.42–27.44)
1.01
8th 26.78
(25.87–27.67)
14.77
(14.76–14.78)
0.55 30.37
(29.62–31.12)
29.35
(29.34–29.36)
0.97
9th 31.85
(31.21–32.50)
17.29
(17.28–17.30)
0.54 32.26
(31.54–32.98)
31.95
(31.94–31.97)
0.99
Highest 10th 33.26
(32.23–34.22)
20.91
(20.84–20.98)
0.63 36.50
(35.66–37.34)
36.47
(36.43–35.61)
1.00
N=144,018 analysis cohort with complete data on all variables included in any model. The cohort is split into 10ths of the distribution of the linear predictor for each of
the two prediction models. For example, for the Templeton prediction model the observed and predicted are compared by 10th of the Templeton linear predictor.
aTempleton: As in reference [7], to date the only externally validated prediction model (Text S1).
bNovel model: Using the same variables as Templeton but allowing them to have different multivariable coefficients to those originally derived by Templeton and
including terms for all causes of infertility (rather than just tubal versus other as in the original Templeton) and four additional predictors: type of hormonal
preparation, whether egg came from patient or donor, number of treatment cycles, and whether ICSI was used with the IVF (Text S2).
doi:10.1371/journal.pmed.1000386.t003
Table 4. Examples of risk prediction in women.
Example Couples
Estimate of Probability of Live
Birth after IVF per 100 Cycles
A. The woman is 40 y old and the couple have been trying to conceive for over 11 y. They have
had four previous unsuccessful IVF treatments (two of which resulted in pregnancy but not a live birth).
The couple’s cause of infertility is a male problem and they have been treated with ICSI. They are now
wishing to embark on their fifth treatment cycle. The woman’s own oocytes will be used and the
hormonal preparation is gonadotrophin.
4.8/100 cycles
B. If we take the same couple as in A but change the treatments so that a donor oocyte is used and
the hormonal preparation is hormone replacement (all other characteristics stay the same as in A)
16.7/100 cycles
C. The woman is 33 and the couple started trying to conceive 5 y ago after the live birth of their son,
which was a spontaneous pregnancy. The couple’s cause of infertility is unknown. They will not be
treated with ICSI; the woman’s own oocytes will be used and the hormonal preparation will be
gonadotrophins. This will be their first treatment cycle.
29.8/100 cycles
D. If we take the same couple as in C but change the treatments so that ICSI will be used, with a donor oocyte
and hormone replacement as the hormonal preparation (all other characteristics stay the same as in A).
43.5/100 cycles
These examples are plausible in terms of the types of patients regularly seen in IVF clinics, and they show the influence of couple characteristics (compare A to C and B
to D) and of treatment effects (compare B to A and D to C), and of both of these combined (compare D to A).
doi:10.1371/journal.pmed.1000386.t004
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Table 5. Multivariable associations of potential risk factors with preterm birth, low birth weight and macrosomia amongst
singleton births following IVF.
Characteristic Categories
Multivariable Association with
Preterm Birth; N=24,096 in
Analyses with n=2,070 Cases
of Preterm Birth
Multivariable Association with
Low Birth Weight; N=21,804
in Analyses with n=2,100
Cases of Low Birth Weight
Multivariable Association with
Low Birth Weight; N=21,950 in
Analyses with n=2,246 Cases of
Macrosomia
Odds Ratio
(95%CI) p-Value
Odds Ratio
(95%CI) p-Value
Odds Ratio
(95%CI) p-Value
Age, y 18–34 1 0.12 1 0.04 1 0.01
35–37 0.90 (0.80–1.00) 0.87 (0.78–0.97) 1.14 (1.03–1.27)
38–39 0.87 (0.75–1.00) 0.86 (0.74–0.99) 1.09 (0.95–1.25)
$40 0.93 (0.77–1.10) 0.96 (0.80–1.15) 1.25 (1.06–1.48)
Duration of
infertility, y
,1 1.05 (0.73–1.49) 0.004 0.86 (0.58–1.25) 0.01 0.81 (0.56–1.17) 0.20
1–3 0.96 (0.86–1.07) 0.90 (0.80–1.00) 0.90 (0.81–0.99)
4–6 1 1 1
7–9 1.17 (1.02–1.35) 1.07 (0.93–1.24) 1.02 (0.89–1.16)
$9 1.25 (1.07–1.46) 1.16 (1.00–1.36) 0.93 (0.80–1.09)
Cause Unknown 1 ,0.001 1 0.02 1 0.002
Tubal only 1.22 (1.06–1.41) 1.12 (0.97–1.30) 1.06 (0.91–1.22)
Anovulatory only 1.14 (0.95–1.37) 1.19 (1.00–1.42 1.04 (0.86–1.25)
Endometriosis only 0.86 (0.65–1.14) 1.04 (0.80–1.35) 0.96 (0.73–1.25)
Cervical only 9.09 (2.01–41.13) 15.62 (2.59–94.06) 10.46 (1.46–74.85)
Male only 0.95 (0.83–1.09) 1.02 (0.89–1.17) 1.22 (1.07–1.39)
Combination known
causes
1.19 (1.00–1.41) 1.15 (0.97–1.36) 0.92 (0.77–1.11)
Previous
unsuccessful
IVF, number
0 1 0.44 1 0.37 1 0.95
1 0.75 (0.50–1.15) 0.85 (0.56–1.29) 0.92 (0.77–1.10)
2 0.80 (0.50–1.30) 0.82 (0.51–1.32) 0.92 (0.61–1.38)
$3 0.66 (0.40–1.11) 0.63 (0.38–1.06) 0.98 (0.61–1.58)
Mutually
exclusive
categories of
previous IVF and
obstetric history
No previous IVF, 0
pregnancy
1 0.11 1 0.004 1 ,0.001
No previous IVF, at least
1 pregnancy, 0 live births
1.15 (0.40–1.11) 1.13 (1.00–1.27) 1.23 (1.09–1.39)
No previous IVF, at
least 1 pregnancy,
at least 1 live birth
0.99 (0.84–1.16) 0.83 (0.70–0.98) 1.28 (1.11–1.49)
Previous IVF, 0 pregnancy 1.48 (0.95–2.30) 1.54 (1.00–2.39) 0.97 (0.63–1.49)
Previous IVF, at least 1
pregnancy, 0 live birth
1.30 (0.93–1.80) 1.37 (0.99–1.91) 1.02 (0.72–1.43)
Previous IVF, at least
1 pregnancy, at least
1 live birth
1.02 (0.55–1.38) 0.89 (0.67–1.17) 1.30 (1.03–1.63)
Hormonal
preparation
Antioestrogen 1 0.11 1 0.77 1 0.86
Gonadatrophin 0.87 (0.55–1.39) 1.18 (0.71–1.97) 1.08 (0.64–1.83)
Hormone replacement 1.07 (0.63–1.82) 1.24 (0.69–2.21) 1.15 (0.64–2.07)
Cycle number 1 1 0.43 1 0.17 1 0.04
2 1.00 (0.89–1.13) 0.96 (0.85–1.08) 1.07 (0.96–1.20)
$3 0.92 (0.81–1.05) 0.89 (0.78–1.01) 1.17 (1.04–1.31)
Source of egg Donor 1 ,0.001 1 ,0.001 1 0.16
Patient 0.41 (0.26–0.64) 0.42 (0.26–0.68) 0.68 (0.39–1.17)
Treatment type IVF 1 0.05 1 0.05 1 0.46
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of which are independently associated with reduced odds of live
birth. The detrimental impact of prolonged infertility suggests that
early recourse to treatment is appropriate and that extended
treatment waiting times, for example whilst trying lifestyle
interventions, might militate against eventual success. The marked
reduction in the success of the second cycle but then a relative
plateau is in contrast to previous reports, which suggested a subtle
decline with increasing cycle number [7]. This difference may
indicate that previous declines in success rates with increasing
cycle number principally reflected increasing maternal age, which
we have adjusted for.
In keeping with all previous reports, live birth rates decline with
increasing maternal age [2,4,7,23]. By contrast, ours is the first
study that we are aware of to find that, in women with successful
IVF delivery of a singleton live birth, younger maternal age is
associated with increased risk of low birth weight. This latter
finding is however, in keeping with the recent observation that
maternal age is positively associated with first trimester growth
[25], which if impaired is an important determinant of later
adverse perinatal outcome [26,27]. For older women, the use of
donor oocytes is a successful strategy for the attainment of a live
birth, however, we identify that donor oocyte recipients have a
marked increase in the risk of delivering a preterm or low birth
weight infant. This may reflect the primary relationship between
ovarian senescence and vascular function. Premature and natural
menopause have both been associated with widespread vascular
dysfunction, dyslipidaemia, a proinflammatory phenotype, and an
increased risk of cardiovascular events [28,29,30]. These same
factors have been implicated in the aetiology of fetal growth
restriction and preeclampsia, the major determinants of preterm
birth [31]. Furthermore, increased incidence of these complica-
tions have been reported in young and old donated oocyte
recipients [32,33]. With respect to macrosomia the associations
with older maternal age may reflect higher maternal socioeco-
nomic class due to deferred child bearing or increased maternal
obesity, both of which would be contribute to improved fetal
nutrition. Similarly, a previous successful pregnancy would be
associated with potential maternal weight retention and thereby
increased fetal weight in subsequent pregnancies [34].
We examined the associates of preterm birth (,37 weeks the
established definition of preterm). Although it is possible that
obstetricians may consider IVF pregnancies as precious and have a
lower threshold for iatrogenic preterm birth, we think this is
unlikely because of the established associations of prematurity with
neonatal respiratory complications [35,36], and our finding that
similar associations were also found for extreme preterm birth
support this assumption. In the UK since 2005 only two embryos
are allowed to be replaced under the age of 40 to reduce the risks
of preterm birth and low birth weight, which are associated with
multiple pregnancies. We have restricted the analysis of perinatal
outcomes to delivery of a singleton pregnancy only because of the
relevance of understanding risk factors associated with these
outcomes in couples requiring IVF even when there is a singleton
pregnancy. Few previous studies have examined the relationship of
couple and treatment characteristics with gestational age and birth
weight after live singleton IVF birth; our findings highlight
important areas for further research aimed at maximising the
success of IVF in terms of a healthy-weight, term live birth.
We demonstrate that a previous live birth as a consequence of
IVF has an even greater effect on the prospect of successful assisted
conception therapy than does previous spontaneous conception.
Although many couples undergoing assisted conception feel
encouraged by achieving a pregnancy, even if it subsequently
results in fetal loss, we found no beneficial or negative effect of a
history of a nonviable pregnancy on live birth. This suggests that
embryonic chromosomal errors, rather than a defective maternal
environment, may be primarily responsible.
Our work has a number of strengths. We have considered a
range of anamnestic couple characteristics simultaneously with
respect to validated live birth and perinatal outcomes rather than
one or two in isolation. As a result, our data give a better overall
reflection of predictive abilities, or lack thereof, for many factors.
The size of our study was extremely large compared to other
such studies in the literature. Finally, we considered a relevant
multivariable historical model for consistency of findings before
developing and assessing a novel prognostic model.
We acknowledge, however, a number of limitations. Data were
not complete on 12% of the eligible cohort; however, univariable
analysis was similar in the whole cohort, and multivariable
multiple imputation did not alter the overall conclusions (results
available from authors on request). Treatment cycles rather than
individual patients were identified because of concerns regarding
confidentiality and breach of the terms of the HFEA Act, and
therefore it was not possible to examine the effect of multiple cycles
within one patient or to use robust standard errors that take
account of clustering of women. However, the previous HFEA
analysis could account for clustering and did not show a significant
effect as compared with per treatment cycle [7]. Maternal age was
supplied in categories because of recent concerns over confiden-
tiality; however, our findings of a decline in live birth rates with
increasing age are in keeping with the previous analysis of the
HFEA database and population reports [1,7,37]. We accept that
the cause of infertility may have been underinvestigated or
misreported [38], although for male factors this was cross-
Characteristic Categories
Multivariable Association with
Preterm Birth; N=24,096 in
Analyses with n=2,070 Cases
of Preterm Birth
Multivariable Association with
Low Birth Weight; N=21,804
in Analyses with n=2,100
Cases of Low Birth Weight
Multivariable Association with
Low Birth Weight; N=21,950 in
Analyses with n=2,246 Cases of
Macrosomia
Odds Ratio
(95%CI) p-Value
Odds Ratio
(95%CI) p-Value
Odds Ratio
(95%CI) p-Value
IVF and ICSI 0.89 (0.80–1.00) 0.89 (0.80–1.00) 0.96 (0.86–1.07)
Cycles included in analyses are from couples for whom data were complete on all variables and who experienced a singleton birth after IVF. For associations with low
birth weight, those with macrosomia as an outcome are removed so that low birth weight is compared with normal birth weight, and similarly for macrosomia, those
with low birth weight are removed so that macrosomia is compared with normal birth weight. The results are with mutual adjustment for all variables in the first
column. In addition, for preterm birth, results are adjusted for mean birth weight and for low birth weight and macrosomia for mean gestational age. p-Values are
likelihood ratio tests of null hypothesis that the odds are the same for each category (i.e., they do not assume linearity).
doi:10.1371/journal.pmed.1000386.t005
Table 5. Cont.
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validated with the use of ICSI, and for tubal disease our observed
decrease in success rate is consistent with the control arm of
randomised controlled trials of salpingectomy prior to IVF [39],
suggesting that these data are accurate.
For the main analyses with successful birth as the outcome we
included both single and multiple pregnancy, i.e. our outcome was at
least one live birth irrespective of whether there was one or more heart
beats at 8 wk. Our reasons for doing this were, first, that this is a
relevant outcome for infertile couples and, second, this was the
outcome used in the study that developed the established prediction
model, and therefore we wanted to test this model with the same
outcome. Note that restriction of the data to pregnancies in which only
one fetal sac was evident at 8 wk gestation produced similar results.
Finally, we acknowledge lack of external validation of our model.
Nonetheless, we believe that this model will improve the ability to
stratify contemporary couples seeking IVF on the basis of low,
moderate, or high likelihood of success. This is of particular relevance
to couples willing to consider all therapeutic options, including use of
donor oocytes, as there is a 5-fold difference in live birth between the
lowest and highest decile of our prediction model. To facilitate
validation of the model we are currently generating a free web-based
prediction tool (http://www.IVFpredict.com) and iPhone/Android
application (IVFpredict) for widespread use of our new prediction
tool. These will acknowledge the current lack of external validation
and will request provision of anonymised data (all variables included
in the prediction model, country of treatment, and outcome) that in
the coming years we will use as a means of external validation of this
model. We have included full model details in Text S2 thereby
facilitating model validation by other research groups.
In conclusion, we show that baseline couple and treatment
characteristics can provide a basis for counselling and informing
couples of their likely prognosis in terms of low, moderate, or high
odds of success (see Table 4).
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Editors’ Summary
Background. Worldwide, more than 10% of couples are
infertile. Sometimes there is no obvious reason for a couple’s
inability to have children but, for many couples, problems
with their eggs or sperm prevent ‘‘fertilization’’—the union
of an egg and a sperm that leads, eventually, to the birth of a
baby. Until recently, little could be done to help infertile
couples. Then, on the 25 July 1978, the world’s first ‘‘test-
tube baby’’ was born. Since then, 4 million babies have been
born through in vitro fertilization (IVF). In IVF, mature eggs
are collected from the woman (or from an egg donor if the
woman cannot make her own eggs) after a course of special
hormones, and they are mixed in a dish with her partner’s
sperm. If her partner has a low sperm count or abnormal
sperm, a single sperm can be injected directly into the egg in
a procedure called intracytoplasmic sperm injection (ICSI),
which became widely available in the mid 1990s, or sperm
from a donor can be used. Finally, a number (depending on
the country) of embryos (eggs that have begun to divide and
develop) are put back into the woman where, hopefully, they
will establish a successful pregnancy.
Why Was This Study Done? Not every attempt at IVF is
successful. In the US and the UK, IVF is successful in about a
third of women under 35 years old but in only 5%–10% of
women over the age of 40. It would be useful to have a way
to predict the likelihood of a live birth after IVF for individual
couples. Such a ‘‘prediction model’’ would facilitate patient
counseling, clinical decision making, and the allocation of IVF
resources. In this study, the researchers use information
on IVF cycles collected by the Human Fertilisation and
Embryology Authority (HFEA), which regulates IVF in the UK,
to assess the extent to which the characteristics of infertile
couples and the treatment they receive can be used to
predict live birth after IVF. They also use these data to
identify which factors are associated with preterm delivery,
low birthweight, and macrosomia (the birth of an unusually
large baby), three undesirable birth characteristics.
What Did the Researchers Do and Find? Between 2003
and 2007, 163,425 IVF cycles were completed in the UK,
23.4% of which resulted in at least one live birth. The
researchers used the data collected by the HFEA on 144,018
of these cycles (the other cycles had missing data) to
develop a multivariable logistic regression prediction model
(a type of statistical model) for the outcome of IVF.
According to this model, a decreased chance of at least
one live birth was associated with several factors including
increasing maternal age, increasing duration of infertility,
and the use of the woman’s own oocytes. By contrast, a
previous IVF live birth and the use of ICSI were associated
with increased chances of success. Importantly, compared
with an established multivariable prediction model, which
was developed before the introduction of ICSI, the
researchers’ new prediction model predicted the chance of
a live birth following IVF with greater accuracy. Finally, the
researchers report that the chances of preterm and low
birthweight after IVF were increased if donor eggs were
required and ICSI was not used, that an increased risk of
macrosomia was associated with increasing maternal age
and with a history of previous live births, and that all three
undesirable birth characteristics were associated with
infertility due to cervical problems.
What Do These Findings Mean? These findings indicate
that couple- and treatment-specific factors can be used to
provide infertile couples with an accurate assessment of
whether they have a low or high chance of a successful
outcome following IVF. The prediction model developed
here provides a more accurate assessment of likely outcomes
after IVF than a previously established model. Furthermore,
because the new model considers the effect of ICSI on
outcomes, it should be more useful in contemporary
populations than the established model, which does not
consider ICSI. However, before this new prediction model
is used to guide clinical decisions and to counsel patients,
it needs to be validated using independent IVF data.
To facilitate the external validation of their model, the
researchers are currently generating a free web-based
prediction tool and iPhone application (IVFpredict).
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000386.
N The Human Fertilisation and Embryology Authority pro-
vides information on IVF and IVF statistics for the UK
N The UK National Health Service Choices website provides
information for patients on infertility and on IVF
N The American Pregnancy Association has information for
patients on infertility and on IVF
N MedlinePlus has links to further resources on infertility and
IVF (in English and Spanish)
N The history of the development of IVF is described on the
Nobel Prize website
N The prediction tool that was used in this study is at http://
www.IVFpredict.com
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